Setomimycin

Setomimycin is a potent antibiotic. Setomimycin inhibits the SARS-CoV-2 Mpro enzyme with an IC₅₀ value of 12.02 µM. Setomimycin shows anti-inflammatory and antioxidant properties. Setomimycin shows antiproliferative and antitumor activity^[1][2]. IC50 & Target:IC₅₀: 12.02 µM (SARS-CoV-2 Mpro)^[1] In Vitro: Setomimycin (0.01-1 µM) inhibits the release of cytokines IL-1β, IL-6 and TNF-α and nitric oxide release from LPS stimulated RAW 264.7 cells in a dose-dependent manner^[1].
Setomimycin (compound 1) shows antimicrobial activity with MICs of 8, 4, 16, 4 μg/mL for Staphylococcus aureus, Bacillus cereus, Bacillus subtilis, Micrococcus luteus, respectively^[2].
Setomimycin (0-100 µM; 5 days) shows antiproliferative activity and inhibits colony formation^[2].
Setomimycin (4, 5.5, 7 µM) decreases the protein expression of p-MEK, p-ERK, Bcl-2, increases the expression of Par-4^[2]. In Vivo: Setomimycin (20 mg/kg; i.p.; alternate days for two weeks) shows antitumor activity in mice^[2].
Pharmacokinetic Parameters of Setomimycin in female BALB/c mice^[2].

Pharmacokinetic parameters	Value
Cmax (ng/ml)	694 ± 62
Tmax (h)	0.3 ± 0.1
T1/2 (h)	2.3 ± 0.5
AUC0-t (ng.h/mL)	2613 ± 111
AUC0-α (ng.h/mL)	2734 ± 108
Vd (L/Kg)	24 ± 4
Cl (L/h/Kg)	7.4 ± 0.3

Female BALB/c mice, 20 mg/kg ip (1 % DMSO +30 % PEG-200 + 2 % Tween 80 + q.s. water (v/v))^[2]